Find insight on Samsung Biologics, China biotech companies and more in the latest Market Talks covering Health Care.

Samsung Biologics announced on Thursday that it will create a new holding company, Samsung Epis Holdings, through a simple division. This is to separate the CDMO business from the biosimilar and ...

Samsung Biologics, Celltrion lead Korean pharma sector with salaries over 100 million won. Samsung and Celltrion dominate the Korean pharmaceutical industry with record-breaking employee earnings ...

- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing ...

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan.. Investors saw the plan — which will ...

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic ...

Samsung Biologics operates with manageable financial health in our view. Its debt/EBITDA ratios were 1.8, 1.5, and 1.0 times for 2021, 2022, and 2023, respectively.

Samsung Biologics, the giant South Korea-based CDMO, reported an all-time earnings high in the first quarter of this year.. The company reported that consolidated sales, which give an overall view ...

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to ...

Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received 'Leadership' status and an A- rating for water ...

Korean CDMO juggernaut Samsung Biologics continued its sales surge in the second quarter, with its biosimilars subsidiary, Samsung Bioepis, doing much of the heavy lifting. For the period, Samsung ...

Samsung Biologics profits surge after flurry of major contract wins. Samsung Biologics takes full ownership of Samsung Bioepis . Samsung Biologics gets full custody over Samsung Bioepis. Samsung ...